Literature DB >> 9738724

Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: a randomized trial.

F H Bloomfield1, D B Knight, J E Harding.   

Abstract

OBJECTIVE: We hypothesized that a pulsed course of dexamethasone would result in better linear growth than a 42-day reducing course in preterm infants at risk for chronic lung disease of prematurity. STUDY
DESIGN: Forty infants with a birth weight of < or =1,250 g who required mechanical ventilation at 7 days of age were randomly assigned to a repeatable 3-day pulse course of dexamethasone commencing immediately or a 42-day (long) course commencing at 14 days of age if they still required mechanical ventilation and supplemental oxygen. The primary outcome measure was linear growth at 36 weeks' postmenstrual age measured by knemometry.
RESULTS: There was no difference in lower leg length at 36 weeks' postmenstrual age. Infants receiving the pulse course had lower rises in blood pressure, less myocardial hypertrophy, and less adrenal suppression. However, more infants required supplemental oxygen at 28 days' postnatal age (14/18 vs 8/21, P < .05) and 36 weeks' PMA (8/16 vs 5/20, P = .12).
CONCLUSION: In preterm infants at risk for chronic lung disease, a pulsed course of dexamethasone has fewer side effects than a long course but may be less effective at preventing chronic lung disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738724     DOI: 10.1016/s0022-3476(98)70277-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  The fetal and neonatal hypothalamic-pituitary-adrenal axis.

Authors:  P C Ng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease.

Authors:  D L Armstrong; J Penrice; F H Bloomfield; D B Knight; J A Dezoete; J E Harding
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

Review 3.  Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use.

Authors:  David G Grier; Henry L Halliday
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Anne Pmc De Jaegere; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

5.  Exposure to repeat doses of antenatal glucocorticoids is associated with altered cardiovascular status after birth.

Authors:  L F J Mildenhall; M R Battin; S M B Morton; C Bevan; C A Kuschel; J E Harding
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-09-20       Impact factor: 5.747

Review 6.  Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Susanne Hay; Brett J Manley; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2021-11-11

Review 7.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24

8.  Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

Authors:  Viraraghavan Vadakkencherry Ramaswamy; Tapas Bandyopadhyay; Debasish Nanda; Prathik Bandiya; Javed Ahmed; Anip Garg; Charles C Roehr; Sushma Nangia
Journal:  JAMA Pediatr       Date:  2021-06-07       Impact factor: 16.193

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.